Why the study?
Residual CVD risk persists even in patients reaching treatment targets, prompting interest in metabolic variable variability to address this risk.
Does the variability of metabolic risk factors increase the risk of cardiometabolic outcomes and mortality independent of mean levels?
Does the variability of metabolic risk factors increase the risk of cardiometabolic outcomes and mortality independent of mean levels?
Beyond achieving target mean levels of metabolic risk factors, minimizing the variability of glucose, cholesterol, blood pressure, and body weight may be an important therapeutic target to further reduce residual cardiovascular risk.
Metabolic variability may contribute to residual CVD risk in diabetes; leaves open whether targeting it improves outcomes.
Despite strenuous efforts to reduce cardiovascular disease (CVD) risk by improving cardiometabolic risk factors, such as glucose and cholesterol levels, and blood pressure, there is still residual risk even in patients reaching treatment targets. Recently, researchers have begun to focus on the variability of metabolic variables to remove residual risks. Several clinical trials and cohort studies have reported a relationship between the variability of metabolic parameters and CVDs. Herein, we review the literature regarding the effect of metabolic factor variability and CVD risk, and describe possible mechanisms and potential treatment perspectives for reducing cardiometabolic risk factor variability.
No takes yet. Share an insight, caveat, or question.
Park et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: